AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04311788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prophylactic self gripping mesh
Description: Prophylactic self gripping mesh, Propgrip by Medtronic.
Study NCT04311788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Slowly absorbable continuous monofilament suture
Description: Fascial closure by continuous slowly absorbable 4:1 suture
Study NCT00673244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: One dose: 1 mg/kg (iv)if the patient is furosemide naive or 1.5 mg/kg (iv) if patient is not furosemide naive.
Study NCT02558231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Macitentan
Description: Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.
Study NCT02558231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.
Study NCT02558231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tadalafil
Description: Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.
Study NCT02558231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.
Study NCT02558231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Used double-blind in the triple oral treatment arm, 200 microgram tablet, 1-8 tablets b.i.d.
Study NCT01250457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical Timolol
Description: topical Timolol 0.5% solution applied twice daily
Study NCT05768542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Injection
Description: If heart rate below 60, give 5 mg IV. If heart rate above 60, give 5 mg IV and repeat until heart rate below 65 or 20 mg given in total or systolic blood pressure below 110 mmHg.
Study NCT05768542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 5 ml given IV
Study NCT02469727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Participants will use the FitBit device to track their physical activity
Study NCT01374295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video
Description: watch a 3 minute video
Study NCT01374295 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard education
Description: Receives standard verbal education from healthcare provider
Study NCT03572166 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Arginine infusion
Description: Intravenous Infusion of Arginine is given, copeptin measurement will be collected before and 60minutes after start of infusion
Study NCT03572166 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline infusion
Description: Intravenous Infusion of hypertonic Saline is given, copeptin measurement will be collected before and once Plasma sodium rises above 149mmol/l
Study NCT03579966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifampridine Phosphate
Description: tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
Study NCT02379780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: USG guided Subcostal TAP block
Description: Ultrasonography Assisted Subcostal TAP blockage: In plane technique was applied and 22 G needle (BRAUN Stimuplex D Plus 0,71\*50 mm 22G\*2) was used. Intravascular injection was eliminated after the passage of rectus sheath by negative aspiration. 0,5-1 ml local anesthetic was applied directly to confirm the right place. 10 cc bupivacain ( 0,5 % Marcain flacon, Astra Zeneca, Sweeden) and 5 cc lidocaine was injected to the site. The same procedure was applied to the opposite site.~we investigated amount of TIVA during the operation, postoperative Visual Analog Scores and the time that the pain free time.
Study NCT02379780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: USG guided Paravertebral Block
Description: Ultrasonoraphy assisted Thoracic Paravertebral blockage application: In-plane or out-of-plane technique was used with stimuplex needle (BRAUN Stimuplec D Plus 0,71\*50 mm 22 G\* 2'', 15°). Popping sensation that was felt by the penetration of the internal intercostal membrane, guided to paravertebral space. Intravascular injection was eliminated by negative aspiration. 0,5 - 1 ml local anesthetic injection was administered to show the displacement of pleura downward that confirmed the place of the needle in the right place. Then 10 cc bupivacain (% 0.5 Marcaine® flacon, Astra Zeneca, Sweeden) and 5 cc lidocaine was injected to the site.~we investigated amount of TIVA during the operation, postoperative Visual Analog Scores and the time that the pain free time.
Study NCT04495283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.
Study NCT04495283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
Study NCT04495283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo 1
Description: Placebo for APAP
Study NCT04495283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo 2
Description: Placebo for combination
Study NCT01571076 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: PGS
Description: Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
Study NCT01571076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged culture
Description: The embryos will be in prolonged culture and on going embryos transferred on Day 5 .
Study NCT01571076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged culture
Description: Prolonged culture of the embryos and posterior transfer of ongoing Day 5 blastocysts.
Study NCT03731052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 188-0551 Spray
Description: Topical Spray containing active drug
Study NCT03731052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Spray
Description: Topical Spray containing no active drug
Study NCT04656808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guilt Focused Intervention
Description: Psychotherapy, group intervention
Study NCT04656808 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: Psychotherapy, group intervention
Study NCT01564823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole: 250 mg/8h. 3 months.
Study NCT01564823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole 250 mg/8h 3 months
Study NCT01564823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Azathioprine: 2.5 mg/kg of weight/day. 3 months.
Study NCT01564823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab 160 mg then 80 mg. After 2 wk: 40 mg as maintenance.
Study NCT00415441 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy program
Study NCT00415441 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo physiotherapy treatment
Study NCT01806818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirisone 50mg or placebo TID
Description: 3 times a day after meals for 1 week
Study NCT01806818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epirisone 50mg or placebo TID
Description: 3 times a day after meals for 1 week
Study NCT04296058 — intervention group
Intervention type: OTHER
Intervention: microvessel density
Description: the vessel numbers in high power field with Anti-CD31 staining in tumor specimen
Study NCT01350492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: 16 weeks of resistance exercise training for the treatment of chronic muscle pain compared to wait-list control
Study NCT00993083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1
Description: Intramuscular injection at 1.5 x 10\^8 pfu/ml at day 0
Study NCT05827510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-585F
Description: BTL-585F device with BTL-585-4 applicator
Study NCT01842672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Dose Escalation of Clofarabine
Study NCT01842672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Study NCT03149146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Making (CDM) Workshop
Description: Participants will be provided the Clinical Decision Making workbook which will be used as a guideline to practice decision making. A workshop was chosen rather than other methods of presenting the guideline so that participants could receive feedback and guidance from the instructors and from the other participants. Active learning educational environment will be encouraged and the workshop require group and individual participation and also assist the participants in reflection on their decisions.
Study NCT04763694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifocal soft contact lenses
Description: Myopic subjects wore multifocal soft contact lenses for 12 months
Study NCT06258603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral care bundle
Description: In the first stage, oral health was evaluated and data about the patient was collected.~In the second stage, an oral care bundle containing an oral care combination was applied to the experimental group. According to this bundle application, patients were received tooth brushing (with chlorhexidine solution) and ice water application twice a day and moisturizing attempts 4 times a day.~In the 3rd stage, saliva pH, dry mouth (amount of salivation) and ventilator associated pneumonia development status of the experimental group patients were evaluated.~Measurements were made by the researcher using the Bedside Oral Exam scale, pH (power of hydrogen) strip and Schirmer Tear Test Strip.~Data regarding whether patients were diagnosed with ventilator associated pneumonia were obtained from the Infection Control Committee.
Study NCT06258603 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: clinical oral care
Description: In the first stage, oral health was evaluated and data about the patient was collected.~In the second stage, routine oral care protocol used in intensive care unit was applied to patients by the patients' primary nurse. According to this application, patients were received oral care using tongue depressor with wrapped in gauze and chlorhexidine solution 4 times a day.~In the 3rd stage, saliva pH (power of hydrogen), dry mouth (amount of salivation) and ventilator associated pneumonia development status of the experimental group patients were evaluated.~Measurements were made by the researcher using the Bedside Oral Exam scale, pH (power of hydrogen) strip and Schirmer Tear Test Strip.~Data regarding whether patients were diagnosed with ventilator associated pneumonia were obtained from the Infection Control Committee.
Study NCT03886987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Non Sterile Powder Free Nitrile Examination Gloves
Description: Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
Study NCT00902031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docusate Sodium, Sennoside
Description: Docusate sodium: given in capsule form (100 mg/capsule), at a dosage of 200 mg, taken twice daily for 10 days.~Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.
Study NCT00902031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sennoside + Placebo
Description: Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.~Placebo: will be taken in capsule form, similar in size, shape, and color to docusate, taken twice daily for 10 days
Study NCT01307839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% lidocaine patch
Description: Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours.
Study NCT01307839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours
Study NCT03275636 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells
Description: Hematopoietic stem cell transplantation with PBSC
Study NCT03275636 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral blood stem cells
Description: Hematopoietic stem cell transplantation with PBSC
Study NCT04401865 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Description: Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
Study NCT04401865 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Description: Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
Study NCT03255655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Therapeutic Ultrasound Treatment - ITU
Study NCT03255655 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intense Therapeutic Ultrasound Treatment - ITU
Study NCT01673243 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire data will be collected one time from parents who enroll on the study during their child's regular clinical visit. We will use a cross-sectional design to estimate the proportion of smoking parents of children with or surviving cancer, or sickle cell disease (SCD) who are willing to participate in tobacco trials, hypothetically offered in the context of their child's medical care. We will also examine the contribution of sociodemographic, environmental, and psychosocial variables, as well as, smoking behaviors as they relate to a parent's willingness to participate in a tobacco-related study.
Study NCT00208806 — intervention group
Intervention type: OTHER
Intervention: congestive heart failure patients
Description: observational echo data on congestive heart failure patients
Study NCT03809988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks
Study NCT03809988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: Endocrine therapy alone (letrozole or fulvestrant)
Study NCT03809988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Endocrine therapy alone (letrozole or fulvestrant)
Study NCT01697566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg.
Study NCT01697566 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken by mouth twice daily for 4, 30 day cycles.
Study NCT01697566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo taken by mouth twice daily for 4, 30 day cycles.
Study NCT01697566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Biopsy
Description: Endometrial biopsies obtained at baseline and after 4 months.
Study NCT01697566 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endometrial Biopsy
Description: Endometrial biopsies obtained at baseline and after 4 months.
Study NCT01697566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.
Study NCT03149146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Decision Making (CDM) Workbook
Description: Participants are encouraged to read and do exercises which was written in the workbook for a week and they also are asked to recall their recent patient case or use their patient as the example case and answer the questions from the Clinical Decision Making workbook.
Study NCT03749824 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: Omega-3 supplement is a highly concentrated fish oil brain booster supplement that helps compensate for the neurocognitive and brain dysfunction which acts as a predisposition to antisocial and violent behaviour. Individuals with antisocial personality disorder have been found to show an 11% reduction in gray matter in the prefrontal cortex (Raine et al. 2001), and structural prefrontal impairments are hypothesised to result in disinhibition of limbic subcortical structures that give rise to aggressive behaviour. Omega-3 (specifically DHA) is known to play a key role in neuronal structure and function.
Study NCT00610649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally administered matching placebo capsules.
Study NCT04252586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: GWP42003-P presented as an oral solution containing cannabidiol in the excipients sesame oil with anhydrous ethanol, sweetener (sucralose), and strawberry flavoring
Study NCT02469727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook group
Description: Participants will receive and post messages and receive badges on the Facebook group
Study NCT03749824 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months.
Study NCT00456625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: Intramuscular injection, 1 dose
Study NCT01419600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8683
Description: Single Dose Inhaled IMP via Turbuhaler
Study NCT01419600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match
Description: Single dose Inhaled Placebo via Turbuhaler
Study NCT02370992 — intervention group
Intervention type: RADIATION
Intervention: I125 brachytherapy
Description: I125 brachytherapy is a standard treatment and will be delivered using routine techniques involving a preimplant volume study followed by implantation of the I125 sources. This is undertaken as an inpatient or day case under general or spinal anaesthetic according to local practice
Study NCT04538131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sensor-driven position-adaptive SCS
Description: Medtronic sensor-driven position-adaptive SCS is capable to monitor the position change and change the parameters accordingly, so as to reduce the position change related side effects.
Study NCT04538131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional SCS
Description: Conventional SCS can not change the parameter when the body position changes.
Study NCT03676010 — intervention group
Intervention type: OTHER
Intervention: Sarcoma and GIST
Description: No Intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
Study NCT03676010 — intervention group
Intervention type: OTHER
Intervention: Breast cancer
Description: No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
Study NCT03676010 — intervention group
Intervention type: OTHER
Intervention: Pancreatic cancer
Description: No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
Study NCT00041470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
Study NCT00041470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 20 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
Study NCT00041470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: 4 mg/kg IV loading dose day 1 of first week followed by 2 mg/kg IV maintenance dose on each subsequent week. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.